Present Status of Serum Tumor Markers in Diagnosis, Prognosis, and Evaluation of Therapy

References

• Gold P, Freedman S O. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439–459
   PubMed Web of Science ®Google Scholar
• Slayter H S, Coligan J E. Electron microscopy and physical characterization of the carcinoembryonic antigen. Biochemistry 1975; 14: 2323–2330
   PubMed Web of Science ®Google Scholar
• VonKleist S, Chavanel G, Burtin P. Identification of an antigen from normal human tissue that crossreacts with the carcinoembryonic antigen. Proc Natl Acad Sci USA 1972; 69: 2492–2494
   PubMed Web of Science ®Google Scholar
• Mach J P, Pusztaszeri G. Carcinoembryonic antigen (CEA): Demonstration of a partial identity between CEA and a normal glycoprotein. Immunochemistry 1972; 9: 1031–1034
   PubMedGoogle Scholar
• LoGerfo P, Krupey J, Hansen H J. Demonstration of an antigen common to several varieties of neoplasia—assay using zirconyl phosphate gel. N Engl J Med 1971; 285: 138–141
   PubMed Web of Science ®Google Scholar
• Moore T L, Kantrowitz P A, Zamcheck N. Carcinoembryonic antigen (CEA) in inflammatory bowel disease. JAMA 1972; 222: 944–947
   PubMed Web of Science ®Google Scholar
• Thompson D MP, Krupey J, Freedman S O, et al. The radio-immunoassay of circulatory carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci USA 1969; 64: 161–167
   PubMedGoogle Scholar
• Fleisher M, Nisselbaum S S, Loftin L, et al. Roche RIA and Abbott EIA carcinoembryonic antigen assays compared. Clin Chem 1984; 30: 200–205
   PubMed Web of Science ®Google Scholar
• Kuroki M, Kuroki M, Koga Y, et al. Monoclonal antibodies to carcinoembryonic antigen: A systemic analysis of antibody specificities by using related normal antigens and evidence for allotypic determinants on carcinoembryonic antigen. J Immunol 1984; 133: 2090–2097
   PubMed Web of Science ®Google Scholar
• Hedin A, Carlsson L, Berglund A, et al. A monoclonal antibody-enzyme immunoassay for serum carcinoembryonic antigen with increased specificity for carcinomas. Proc Natl Acad Sci 1983; 80: 3470–3474
   PubMed Web of Science ®Google Scholar
• Lokich J J, Ellenberg S, Gerson B. Criteria for monitoring carcinoembryonic antigen: Variability of sequential assays at elevated levels. J Clin Oncol 1984; 2: 181–185
   PubMed Web of Science ®Google Scholar
• Ravry M, Moertel C G, Schutt A J, et al. Usefulness of serial serum carcinoembryonic antigen (CEA) determinations during anti-cancer therapy or long-term follow-up of gastrointestinal carcinoma. Cancer 1974; 34: 1230–1234
   PubMed Web of Science ®Google Scholar
• Hansen H J, Snyder Miller J J, et al. Carcinoembryonic antigen (CEA) assay, a laboratory adjunct in the diagnosis and management of cancer. J Hum Pathol 1974; 5: 139–147
   PubMed Web of Science ®Google Scholar
• Dykes P W, King J. Progress report: Carcinoembryonic antigen (CEA). Gut 1974; 13: 1000–1013
   Web of Science ®Google Scholar
• Costanza M E, Saroj D, Nathanson L, et al. Carcinoembryonic antigen: Report of a screening study. Cancer 1974; 33: 583–590
   PubMed Web of Science ®Google Scholar
• Dhar P, Moore T, Zamcheck N, et al. Carcinoembryonic antigen (CEA) in colonic cancer—use in preoperative and postoperative diagnosis and prognosis. JAMA 1972; 221: 31–35
   PubMed Web of Science ®Google Scholar
• LoGerfo P, LoGerfo F F, Barker H G, et al. Tumor-associated antigen in patients with carcinoma of the colon. Am J Surg 1972; 123: 127–131
   PubMed Web of Science ®Google Scholar
• Cullen K J, Stevens D P, Frost M A, et al. Carcinoembryonic antigen (CEA), smoking and cancer in a longitudinal population study. Aust NZ J Med 1976; 6: 279–283
   PubMedGoogle Scholar
• Alexander J C, Jr, Silverman N A, Chretien P B. Effect of age and cigarette smoking on carcinoembryonic antigen levels. JAMA 1976; 235: 1975–1979
   PubMed Web of Science ®Google Scholar
• Mach J P, Jaeger P H, Bertholet M M, et al. Detection of recurrence of large bowel carcinoma by radioimmunoassay of circulating carcinoembryonic antigen (CEA). Lancet 1974; 2: 535–540
   PubMed Web of Science ®Google Scholar
• Holyoke D, Reynoso T, Chut M. Carcinoembryonic antigen (CEA) in patients with carcinoma of the digestive tract. Ann Surg 1972; 176: 559–564
   PubMed Web of Science ®Google Scholar
• Zamcheck N. The present status of CEA in diagnosis, prognosis, and evaluation of therapy. Cancer 1975; 36: 2460–2470
   PubMed Web of Science ®Google Scholar
• Wanebo H J, Rao B, Pinsky C M, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978; 299: 448–451
   PubMed Web of Science ®Google Scholar
• Holyoke E D, Chu T M, Evans J T, . Carcinoembryonic antigen as a tumor marker. Biochemical Markers for Cancer, T M Chu, et al. Marcel Dekker, Inc., New York and Basel 1982; 68–69
   Google Scholar
• Herrera M A, Chu T M, Holyoke E D. Carcinoembryonic antigen (CEA) as a prognostic and monitoring test in clinically complete resection of colorectal carcinoma. Ann Surg 1970; 183: 5–9
   Google Scholar
• Minton J P, Hoehn J L, Gerber D M, et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 1985; 55: 1284–1290
   PubMed Web of Science ®Google Scholar
• Holyoke E D, Chu T M, Evans J T, . Carcinoembryonic antigen as a tumor marker. Biochemical Markers for Cancer, T M Chu, et al. Marcel Dekker, Inc., New York and Basel 1982; 70
   Google Scholar
• Shani A, O'Connell M J, Moertel C G, et al. Serial plasma carcinoembryonic antigen measurements in the management of metastatic colorectal carcinoma. Ann Intern Med 1978; 88: 627–630
   PubMed Web of Science ®Google Scholar
• Goslin R, O'Brien M S, Steele G, et al. Correlation of plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer. Am J Med 1981; 71: 246–253
   PubMed Web of Science ®Google Scholar
• Gitlin D, Boesman M. Sites of serum a-fetoprotein synthesis in the human and in the rat. J Clin Invest 1967; 46: 1010–1016
   PubMed Web of Science ®Google Scholar
• Abelev G I. Alpha-protein in oncogenesis and its association with malignant tumors. Adv Cancer Res 1971; 14: 295–358
   PubMedGoogle Scholar
• Gitlin D, Boesman M. Serum a-fetoprotein, albumin, and G-globulin in the human conceptus. J Clin Invest 1966; 45: 1826–1838
   PubMed Web of Science ®Google Scholar
• Abelev G I, Perova S D, Khramkova N I, et al. Production of embryonal a-globulin by transplantable mouse hepatomas. Transplantation 1963; 1: 174–180
   PubMed Web of Science ®Google Scholar
• Tatarinov Y S. Detection of embryo-specific a-globulin in the blood sera of patients with primary liver tumor. Vopr Med Khim 1964; 10: 90–91
   PubMedGoogle Scholar
• Anderson T, Waldman T A, Javadpour N, et al. Testicular germ-cell neoplasms: Recent advances in diagnosis and therapy. Ann Intern Med 1979; 90: 373–385
   PubMed Web of Science ®Google Scholar
• Bloomer J R, Waldman T A, McLntire K R, et al. Alphafetoprotein in non-neoplastic hepatic disorders. JAMA 1975; 233: 38–41
   PubMed Web of Science ®Google Scholar
• Hirai H. Alpha fetoprotein. Biochemical Markers for Cancer, T M Chu. Marcel Dekker, Inc., New York and Basel 1982; 29
   Google Scholar
• Yachnin S, Hus R, Heinrikson R, et al. Comparison of the physical properties and imunosuppressive effects of hepatoma and fetal human alpha-fetoprotein. Clin Res 1976; 24: 483A
   Google Scholar
• Gold P, Labitan A, Wong H CG, et al. Physicochemical approach to the purification of human a-fetoprotein from the ascites fluid of a hepatoma-bearing patient. Cancer Res 1978; 38: 6–12
   PubMed Web of Science ®Google Scholar
• Vessela R L, Santrach M A, Bronson D, et al. Evaluation of AFP glycosylation heterogeneity in cancer patients with AFP-producing tumors. Int J Cancer 1984; 34: 309–314
   PubMed Web of Science ®Google Scholar
• Ishiguro T, Sugitachi I, Sakaguchi H, et al. Serum alpha-fetoprotein subtractions in patients with primary hepatoma or hepatic metastasis of gastric cancer. Cancer 1985; 55: 156–159
   PubMed Web of Science ®Google Scholar
• A Manual of Quantitative Immunoelectrophoresis, N H Axelsen, J Kroll, B Weeks. Universitetsforla-get, Oslo-Bergen-Tromso 1973
   Google Scholar
• Ruoslahti E, Seppala M. Studies of carcinofetal protein. III. Development of a radioimmunoassay for a-fetoprotein in serum of healthy human adults. Int J Cancer 1971; 8: 374–383
   PubMed Web of Science ®Google Scholar
• Purvis L R, Purvis M. Serum alpha-fetoprotein. VI. The radioimmunoassay. Evidence for the presence of AFP in the serum of normal people and during pregnancy. S Afr Med J 1972; 46: 1290–1297
   PubMed Web of Science ®Google Scholar
• Nichi S, Hirai H. Radioimmunoassay of carcinoembryonic antigen and its related antigen by the sandwich method. Onco-developmental Gene Expression, W H Fishman, S Sell. Academic Press, New York 1976; 567–572
   Google Scholar
• Bellet D H, Wand J R, Isselbacher K J, et al. Serum alpha-fetoprotein levels in human disease: Perspective from a highly specific monoclonal radioimmunoassay. Proc Natl Acad Sci USA 1974; 81: 3869–3873
   Google Scholar
• Waldmann T A, McLntire K R. The use of a radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancy. Cancer 1974; 34: 1510–1520
   PubMed Web of Science ®Google Scholar
• Kurman R J, Norris H J. Endodermal sinus tumor of the ovary: A clinical and pathologic analysis of 71 cases. Cancer 1976; 38: 2404–2419
   PubMed Web of Science ®Google Scholar
• Tsukada Y, Hirai H. Alpha-fetoprotein and albumin synthesis during the cell cycle. Ann NY Acad Sci 1975; 259: 37–46
   PubMed Web of Science ®Google Scholar
• Massayeff R F. Factors influencing alpha-fetoprotein biosynthesis in patients with primary liver cancer and other diseases. Alpha-fetoprotein and Hepatoma, H Hirai, T Miyaji. Tokyo University Press, Tokyo 1973; 3–18
   Google Scholar
• Lehman F G. Prognostic significance of alpha-fetoprotein in liver cirrhosis: Five-year prospective study. Onco-developmental Gene Expression, W H Fishman, S Sills. Academic Press, New York 1976; 407–415
   Google Scholar
• Okuda K, Kotoda K, Obatu H, et al. Clinical observations during a relatively early stage of hepatocellular carcinoma with special reference to serum alpha-fetoprotein levels. Gastroenterology 1977; 69: 226–234
   Web of Science ®Google Scholar
• Matsumoto Y, Suzuki T, Asada I, et al. Clinical classification of hepatoma in Japan according to serial changes in serum alpha-fetoprotein levels. Cancer 1982; 49: 354–560
   PubMed Web of Science ®Google Scholar
• Purves L R, Bershon I, Path F C, et al. Serum alpha-fetoprotein and primary cancer of the liver in man. Cancer 1970; 25: 1261–1270
   PubMed Web of Science ®Google Scholar
• Chen D, Sung J, Shen J, et al. Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 1984; 86: 1404–1409
   PubMed Web of Science ®Google Scholar
• Thompson D, Haddow J. Serial monitoring of serum alpha-fetoprotein and chorionic gonadotropin in males with germ cell tumors. Cancer 1979; 43: 1820–1829
   PubMed Web of Science ®Google Scholar
• Lange P H, McLntire K R, Waldman T A, et al. Serum alpha-fetoprotein and human chorionic gonadotropin in the diagnosis and management of non-seminomatous germ cell testicular cancer. N Engl J Med 1976; 295: 1237–1240
   PubMed Web of Science ®Google Scholar
• Lange P H, McLntire K R, Waldman T A, et al. Alpha-fetoprotein and human chorionic gonadotropin in the management of testicular tumors. J Urol 1977; 118: 593–596
   PubMed Web of Science ®Google Scholar
• Talerman A, Haige W G, Baggerman L. Serum alpha-fetoprotein in diagnosis and management of endodermal sinus tumor and mixed germ cell tumor of the ovary. Cancer 1977; 41: 272–278
   Web of Science ®Google Scholar
• Vogelzang N S, Lange P H, Goldman A, et al. Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res 1982; 42: 4855–4861
   PubMed Web of Science ®Google Scholar
• Borkowski A, Muquardt C. Human chorionic gonadotropin in the plasma of normal non-pregnant subjects. N Engl J Med 1979; 301: 298–302
   PubMed Web of Science ®Google Scholar
• Hussa R, Cole L A. New horizons in HCG detection. Advances in Experimental Medicine and Biology, R A Patillo, R O Hussa. Plenum Press, New York and London 1984; 217–243, No. 176
   Google Scholar
• Pierce G B, Dixon F J, Verney E. Endocrine function of a hetero-transplantable human embryonal carcinoma. Arch Pathol 1959; 67: 204–210
   Google Scholar
• Pierce G B, Midgley A R, Verney E L. Therapy of heterotransplanted choriocarcinoma. Cancer Res 1962; 22: 563–567
   PubMed Web of Science ®Google Scholar
• Lewis J L, Davis R C, Ross G T, et al. Hormonal, immunologic and chemotherapeutic studies of transplantable human choriocarcinoma. Am J Obstet Gynecol 1969; 104: 472–478
   PubMed Web of Science ®Google Scholar
• Hayashi H, Kamlyn T, Shimosato Y, et al. Chemotherapy of human choriocarcinoma transplanted to nude mice. Am J Obstet Gynecol 1978; 131: 548–554
   PubMed Web of Science ®Google Scholar
• Morgan F S, Berkin S, Canfield R E. The amino acid sequence of human chorionic gonadotropin. J Biol Chem 1975; 250: 5247–5288
   PubMed Web of Science ®Google Scholar
• Vaitukaitis J L, Braunstein G D, Ross G T. A radioimmunoassay which specifically measures human gonadotropin in the presence of human luteinizing hormone. Am J Obstet Gynecol 1972; 113: 751–758
   PubMed Web of Science ®Google Scholar
• Braunstein G D, Vaitukaitis J L, Carbone P, et al. Ectopic production of human chorionic gonadotropin by neoplasms. Ann Intern Med 1973; 78: 39–45
   PubMed Web of Science ®Google Scholar
• Navarro C, Corretger S M, Sancho A, et al. Paraneoplastic precocious puberty: Report of a new case with hepatoblastoma and review of the literature. Cancer 1985; 56: 1725–1729
   PubMed Web of Science ®Google Scholar
• Bagshawe K D. Risk and prognostic factors in trophoblastic neoplasms. Cancer 1976; 38: 1373–1375
   PubMed Web of Science ®Google Scholar
• Jones W B. Human chorionic gonadotropin—the ideal tumor marker?. Controversies in Gynecological Oncology, S C Ballen. Hull, Boston 1981; 367–375
   Google Scholar
• Bagshawe K D. Clinical applications of HCG. Human Trophoblast Neoplasms, R A Pattillo, R O Hussa. Plenum Press, New York 1984; 313–324
   Google Scholar
• Hussa R O. Clinical utility of HCG and alpha subunit measurement. Obstet Gynecol 1982; 60: 1–12
   PubMed Web of Science ®Google Scholar
• Bagshawe K D, Wilson H, Dublon P, et al. Follow-up after hydatidiform mole: Studies using radioimmunoassay for urinary human chorionic gonadotropin (HCG). J Obstet Gynecol Br Comm 1973; 80: 461–468
   Google Scholar
• Anderson T, Waldmann T A, Javadpour N, et al. Testicular germ-cell neoplasm: Recent advances in diagnosis and therapy. Ann Intern Med 1979; 90: 373–385
   PubMed Web of Science ®Google Scholar
• Scardino P T, Cox H D, Waldmann T A, et al. The value of serum tumor markers in the staging and prognosis of germ cell tumors of the testis. J Urol 1977; 118: 994–999
   PubMed Web of Science ®Google Scholar
• Braunstein G D, McLntire K R, Waldman T A. Discordance of human chorionic gonadotropin and AFP in testicular teratocarcinoma. Cancer 1973; 31: 1065–1068
   PubMed Web of Science ®Google Scholar
• Perlin E, Engeler J E, Jr, Edsen M, et al. The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal tumors. Cancer 1976; 37: 215–219
   PubMed Web of Science ®Google Scholar
• Picozzi V J, Freiha F S, Hannigan J F, et al. Prognostic significance of a decline in serum human chorionic gonadotropin levels after initial chemotherapy for advanced germ-cell carcinoma. Ann Intern Med 1984; 100: 183–186
   PubMed Web of Science ®Google Scholar
• Richardson R L, Schoumacher R A, Per M F, et al. The unrecognized extragonadal germ cell cancer syndrome. Ann Intern Med 1981; 94: 181–186
   PubMed Web of Science ®Google Scholar
• Potts J T, Jr, Reisfeld R A, Hirsch P F, et al. Purification of porcine thyrocalcitonin. Proc Natl Acad Sci USA 1967; 58: 328–335
   PubMed Web of Science ®Google Scholar
• Deftos L J, Lee M R, Potts J T, Jr. A radioimmunoassay for thyrocalcitonin. Proc Acad Sci USA 1968; 60: 293–299
   PubMed Web of Science ®Google Scholar
• Hirsch P F, Voelkel E F, Munson P L. Thyrocalcitonin: Hypo-calcemic hypophosphatemic principle of the thyroid gland. Science 1964; 146: 412–413
   PubMed Web of Science ®Google Scholar
• Tashjian A H, Wolfe H F, Voelkel E F. Human calcitonin. Immunologic assay, cytologic localization and studies on medullary thyroid carcinoma. Am J Med 1974; 56: 840–849
   PubMed Web of Science ®Google Scholar
• Hennessey J F, Wells S A, Ontjes D A, et al. A comparison of pen-tagastrin injection and calcium infusion as provocative agents for the detection of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1974; 39: 487–495
   PubMed Web of Science ®Google Scholar
• Wells S A, Baylin S B, Lineham W M, et al. Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg 1978; 188: 139–141
   PubMed Web of Science ®Google Scholar
• Hirsch P F, Munson P L. Thyrocalcitonin. Physiol Rev 1969; 49: 548–622
   PubMed Web of Science ®Google Scholar
• Tashjian A H, Jr, Howland B G, Melvin K EW, et al. Immunoassay of human calcitonin. Clinical measurement, relationship to serum calcium and studies in patients with medullary carcinoma. N Engl J Med 1970; 283: 890–895
   PubMed Web of Science ®Google Scholar
• Melvin K EW, Tashjian A H, Jr, Miller H H. Studies in familial (medullary) thyroid carcinoma. Rec Progr Horm Res 1972; 28: 399–470
   PubMedGoogle Scholar
• Wolfe H F, Melvin K EW, Cervi-Skinner S, et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med 1973; 289: 437–441
   PubMed Web of Science ®Google Scholar
• Graze K, Spiler I J, Tashjian A H, Jr, et al. natural history of familial medullary thyroid carcinoma: Effect of a program for early diagnosis. N Engl J Med 1978; 299: 980–985
   PubMed Web of Science ®Google Scholar
• Leape L L, Miller H H, Graze K, et al. Total thyroidectomy for occult familial medullary carcinoma of the thyroid in children. J Pediatr Surg 1976; 11: 831–837
   PubMed Web of Science ®Google Scholar
• Gagel R F, Jackson C E, Block M A, et al. Age-related probability of development of hereditary medullary thyroid carcinoma. J. Pediatr 1982; 101: 941–946
   Web of Science ®Google Scholar
• Vindelov L L, Hansen H H, Christensen I J, et al. Clonal heterogeneity of small cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. Cancer Res 1980; 40: 4295–4300
   PubMed Web of Science ®Google Scholar
• Coombes R C, Hillyard C, Greenberg P B, et al. Plasma-immunoreactive-calcitonin in patients with non-thyroid tumors. Lancet 1974; 1: 1080–1083
   PubMed Web of Science ®Google Scholar
• Cate C C, Douple E B, Andrews K M, et al. Calcitonin as an indicator of the response of human small cell carcinoma of the lung cells to drugs and radiation. Cancer Res 1984; 44: 949–954
   PubMed Web of Science ®Google Scholar
• Bock E, Dissing J. Demonstration of enolase activity connected to the brain specific protein 14–3–2. Scand J Immunol 1975; 4: 31–36, (Suppl 2)
   PubMedGoogle Scholar
• Hullin D A, Brown K, Kynoch P AM, et al. Purification, radioimmunoassay, and distribution of human brain 14–3–2 protein (nervous system-specific enolase) in human tissues. Biochem Biophys Acta 1980; 628: 98–108
   PubMed Web of Science ®Google Scholar
• Moore B W. Chemistry and biology of two proteins, S-100 and 14–3–2, specific to the nervous system. International Review of Neurobiology, Volume 15, C C Pfeiffer, J R Smythies. Academic Press, New York 1972; 215–225
   Google Scholar
• Schmechel D, Marangos P J, Zis A P, et al. Brain enolases as specific markers of neuronal and glial cells. Science 1978; 199: 313–315
   PubMed Web of Science ®Google Scholar
• Marangos P J, Schmechel D E, Parma A M, et al. Measurement of neuron-specific (NSE) and non-neuronal (NNE) isoenzymes of enolase in rat, monkey and human nervous tissue. J Neurochem 1979; 33: 319–329
   PubMed Web of Science ®Google Scholar
• Marangos P J, Polak J M, Pearse A GE. Neuron-specific enolase: A probe for neurons and neuroendocrine cells. Trends Neurosci 1982; 5: 193–195
   Web of Science ®Google Scholar
• Royds J A, Parson M A, Taylor C B, et al. Enolase isoenzyme distribution in the human brain and its tumors. J Pathol 1982; 137: 37–9
   PubMed Web of Science ®Google Scholar
• Schmechel D, Marangos P J, Brightman M. Neuron-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature 1978; 273: 834–836
   Google Scholar
• Kato K, Ishiguro Y, Suzuki F, et al. Distribution of nervous system-specific forms of enolase in peripheral tissues. Brain Res 1982; 237: 441–448
   PubMed Web of Science ®Google Scholar
• Tapia F J, Polak J M, Barbosa A JA, et al. Neuron-specific enolase is produced by neuroendocrine tumors. Lancet 1981; 1: 808–811
   PubMed Web of Science ®Google Scholar
• Ishiguro Y, Kato K, Ito T, et al. Determination of three enolase isozymes and S-100 protein in various tumors in children. Cancer Res 1983; 43: 6080–6084
   PubMed Web of Science ®Google Scholar
• Gu J, Polak J M, Van Noorden S, et al. Immunostaining of neuron-specific enolase as a diagnostic tool for Merkel cell tumors. Cancer 1983; 52: 1039–1043
   PubMed Web of Science ®Google Scholar
• Prinz R A, Bermes E W, Kimmel J R, et al. Serum markers for pancreatic islet cell and intestinal carcinoid tumors: A comparison of neuron-specific enolase, B-human chorionic gonadotropin and pancreatic polypeptide. Surgery 1983; 94: 1019–1023
   PubMed Web of Science ®Google Scholar
• Oskam R, Rijksen G, Lips C JM, et al. Enolase isoenzymes in differentiated and undifferentiated medullary thyroid carcinomas. Cancer 1985; 55: 394–399
   PubMed Web of Science ®Google Scholar
• Inoue M, Ueda G, Nakajima T. Immunohistochemical demonstration of neuron-specific enolase in gynecologic malignant tumors. Cancer 1985; 55: 1686–1690
   PubMed Web of Science ®Google Scholar
• Haimoto H, Takahashi Y, Koshikawa T, et al. Immunohistochemical localization of γ-enolase in normal human tissues other than nervous and neuroendocrine tissues. Lab Invest 1985; 52: 257–263
   PubMed Web of Science ®Google Scholar
• Marangos P J, Goodwin F K, Parma A, et al. Neuron specific protein (NSP) in neuroblastoma cells: Relation to differentiation. Brain Res 1978; 145: 49–58
   PubMed Web of Science ®Google Scholar
• Schmechel D E, Brightman M W, Marangos P J. Neurons switch from non-neuronal enolase to neuron-specific enolase during differentiation. Brain Res 1980; 190: 195–214
   PubMed Web of Science ®Google Scholar
• Wevers R A, Jacobs A AC, Hommes O R. A bioluminescent assay for enolase (EC 4.2.1.11) activity in human serum and cerebrospinal fluid. Clin Chim Acta 1983; 135: 159–168
   PubMed Web of Science ®Google Scholar
• Gerbitz K-D, Summer J, Thallemer J. Brain-specific proteins: Solid-phase immunobioluminescence assay for neuron-specific enolase in human plasma. Clin Chem 1984; 30: 382–386
   PubMed Web of Science ®Google Scholar
• Carney D N, Marangos P J, Ihde D C, et al. Seram neuron-specific enolase: A marker for disease extent and response to therapy of small-cell lung cancer. Lancet 1982; 1: 583–585
   PubMed Web of Science ®Google Scholar
• Ishiguro Y, Kato K, Ito T, et al. Nervous system-specific enolase in serum as a marker for neuroblastoma. Pediatrics 1983; 72: 696–700
   PubMed Web of Science ®Google Scholar
• Johnson D H, Marangos P J, Forbes J T, et al. Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung. Cancer Res 1984; 44: 5409–5419
   PubMed Web of Science ®Google Scholar
• Esscher T, Steinholtz L, Bergh J, et al. Neuron specific enolase: A useful diagnostic serum marker for small cell carcinoma of the lung. Thorax 1985; 40: 85–90
   PubMed Web of Science ®Google Scholar
• Marangos P J, Parma A M, Goodwin F K. Functional properties of neuronal and glial isoenzymes of brain enolase. J Neurochem 1978; 31: 727–732
   PubMed Web of Science ®Google Scholar
• Kato K, Asai R, Shimizu F, et al. Immunoassay of three enolase isozymes in human serum and in blood cells. Clin Chim Acta 1983; 127: 353–363
   PubMed Web of Science ®Google Scholar
• Zeltzer P M, Marangos P J, Sather H, et al. Prognostic importance of serum neuron specific enolase in local and widespread neuroblastoma. Progr Clin Biol Res 1984; 17: 319–329
   Google Scholar
• Prinz R A, Marangos P J. Use of neuro-specific enolase as a serum marker for neuroendocrine neoplasms. Surgery 1982; 97: 887–889
   Google Scholar
• Prinz R A, Marangos P J. Serum neuron-specific enolase: A serum marker for non-functioning pancreatic islet cell carcinoma. Am J Surg 1983; 145: 77–81
   PubMed Web of Science ®Google Scholar
• Wacker W EC, Ulmer D D, Vallee B L. Metalloenzymes and myocardial infarction, II. Malic and lactic dehydrogenase activities and zinc concentrations in serum. N Engl J Med 1956; 255: 449–456
   Web of Science ®Google Scholar
• Goldman R, Kaplan N O, Hall T C. Lactic dehydrogenase in human neoplastic tissues. Cancer Res 1964; 24: 389–399
   PubMed Web of Science ®Google Scholar
• Wroblewski F, LaDue J S. Lactic dehydrogenase activity in blood. Proc Soc Exp Biol Med 1955; 90: 210–213
   PubMed Web of Science ®Google Scholar
• Peake M J, Pejakovic M, Alderman M J, et al. Mechanism of platelet interference with measurement of lactate dehydrogenase activity in plasma. Clin Chem 1984; 30: 518–520
   PubMed Web of Science ®Google Scholar
• Chainurati T, Harinasuta U, Zimmerman H J. Spurious elevation of apparent lactate dehydrogenase activity caused by triamterene. Clin Chem 1973; 19: 1202–1204
   PubMed Web of Science ®Google Scholar
• Acheampong-Mensah D. Persistent increase of serum lactate dehydrogenase activity related to enzyme IgG (lambda) immunoglobulin complex. Clin Chem 1980; 26: 789–790
   PubMed Web of Science ®Google Scholar
• Nagamine M. Serum inactivator to M subunit of lactate dehydrogenase isoenzymes. Clin Chim Acta 1974; 50: 173–179
   Web of Science ®Google Scholar
• Jacobs D S, Robinson R A, Clark G M, et al. Clinical significance of the isomorphic pattern of the isoenzymes of serum lactate dehydrogenase. Ann Clin Lab Sci 1977; 7: 411–421
   PubMed Web of Science ®Google Scholar
• Vanderlinde R E. Measurement of total lactate dehydrogenase activity. Ann Clin Lab Sci 1985; 15: 13–31
   PubMed Web of Science ®Google Scholar
• Hill B R, Levi C. Elevation of a serum component in neoplastic disease. Cancer Res 1954; 14: 513–515
   PubMed Web of Science ®Google Scholar
• Zondag H A, Klein F. Clinical applications of lactate dehydrogenase isozymes: Alterations in malignancy. Ann NY Acad Sci 1968; 151: 578–586
   PubMed Web of Science ®Google Scholar
• Bierman H R, Hill B R, Reinhardt L, et al. Correlation of serum lactic dehydrogenase activity with the clinical status of patients with cancer lymphomas and leukemias. Cancer Res 1957; 17: 660–677
   PubMed Web of Science ®Google Scholar
• Ratcliff C R, Culp T W, Hall F F. Serum lactic dehydrogenase and other enzymes in malignant disease: Comparison with an immunodiagnostic test for cancer. Am J Gastroenterol 1971; 56: 199–208
   PubMed Web of Science ®Google Scholar
• Wood D C, Varela V, Palmquist M, et al. Serum lactic dehydrogenase and isoenzymes in clinical cancer. J Surg Oncol 1973; 5: 251–257
   PubMedGoogle Scholar
• Singh R, Rohatgi A K, Shukla P K. Lactate dehydrogenase activity in ocular tumors. Ann Ophthalmol 1983; 15: 317–319
   PubMed Web of Science ®Google Scholar
• O'Connor D T, Gochman N. Lactic dehydrogenase activity in human pheochromocytoma. JAMA 1983; 249: 383–385
   PubMed Web of Science ®Google Scholar
• Cori C F, Cori G T. The carbohydrate metabolism of tumors. II. Changes in the sugar, lactic acid, and CO2-combining power of blood passing through a tumor. J Biol Chem 1925; 65: 397–405
   Google Scholar
• Boxer G E, Devlin T M. Pathways of intracellular hydrogen transport. Science 1961; 134: 1495–1501
   PubMed Web of Science ®Google Scholar
• Brindley C O, Francis F L. Serum lactic dehydrogenase and glutamic-oxaloacetic transaminase correlations with measurements of tumor masses during therapy. Cancer Res 1963; 23: 112–117
   PubMed Web of Science ®Google Scholar
• Shapira F. Isoenzymes and cancer. Adv Cancer Res 1973; 18: 77–153
   PubMedGoogle Scholar
• Vesell E S, Beam A G. Localization of lactic acid dehydrogenase activity in serum fractions. Proc Soc Exp Biol Med 1957; 94: 96–99
   PubMed Web of Science ®Google Scholar
• von Eyben F E. Biochemical markers in advanced testicular tumors: Serum lactate dehydrogenase, urinary chorionic gonadotropin and total urinary estrogens. Cancer 1978; 41: 648–652
   PubMed Web of Science ®Google Scholar
• Lieskovsky G, Skinner D G. Significance of serum lactic dehydrogenase in stages B and C non-seminomatous testis tumors. J Urol 1980; 123: 516–517
   PubMed Web of Science ®Google Scholar
• Lippert M, Papadopoulos N, Javadpour N. Role of lactate dehydrogenase isoenzymes in testicular cancer. Urology 1981; 18: 50–53
   PubMed Web of Science ®Google Scholar
• Lippert M C, Javadpour N. Lactic dehydrogenase in the monitoring and prognosis of testicular cancer. Cancer 1981; 48: 2274–2278
   PubMed Web of Science ®Google Scholar
• Sheiko M C, Hart W R. Ovarian germinoma (dysgerminoma) with elevated serum lactic dehydrogenase: Case report and review of literature. Cancer 1982; 49: 994–998
   PubMed Web of Science ®Google Scholar
• Brereton H D, Simon R, Pomeroy T C. Pretreatment serum lactate dehydrogenase predicting metastatic spread in Ewing's sarcoma. Ann Intern Med 1975; 83: 352–354
   PubMed Web of Science ®Google Scholar
• Glaubiger D, Makuch R, Schwartz J, et al. Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma. Cancer 1980; 45: 2213–2219
   PubMed Web of Science ®Google Scholar
• Blatt J, Reaman G, Poplack D G. Biochemical markers in lymphoid malignancy. N Engl J Med 1980; 303: 918–922
   PubMed Web of Science ®Google Scholar
• Anderson T, Magrath I, Brereton H, et al. Burkitt's lymphomas: Prediction of early relapse and metabolic complications of therapy. Proc Am Assoc Cancer Res 1974; 15: 169
   Web of Science ®Google Scholar
• Arseneau J C, Canellos G P, Banks P M, et al. American Burkitt's lymphoma: A clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival. Am J Med 1975; 58: 314–321
   PubMed Web of Science ®Google Scholar
• Magrath I, Lee Anderson Y J, et al. Prognostic factors in Burkitt's lymphoma. Importance of total tumor burden. Cancer 1980; 45: 1507–1515
   PubMed Web of Science ®Google Scholar
• Schneider R J, Seibert K, Passe S, et al. Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer 1980; 46: 139–143
   PubMed Web of Science ®Google Scholar
• Ferraris A M, Guintini P, Gaetani G F. Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin's lymphomas. Blood 1979; 54: 928–932
   PubMed Web of Science ®Google Scholar
• Rubery E D, Doran J F, Thompson R J. Brain-type creatine kinase BB as a potential tumor marker: Serum levels measured by radioimmunoassay in 1015 patients with histologically confirmed malignancies. Eur J Cancer Clin Oncol 1982; 18: 951–956
   PubMedGoogle Scholar
• Carney D N, Zweig M H, Ihde D C, et al. Elevated serum creatine kinase BB levels in patients with small cell lung cancer. Cancer Res 1984; 44: 5399–5403
   PubMed Web of Science ®Google Scholar
• Gazdar A F, Zweig M H, Carney D N, et al. Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. Cancer Res 1981; 41: 2773–2777
   PubMed Web of Science ®Google Scholar
• Berggard I, Beam A C. Isolation and properties of low molecular weight β2-globulin occurring in human biological fluids. J Biol Chem 1968; 243: 4095–403
   PubMed Web of Science ®Google Scholar
• Cresswell P, Springer T, Strominger J L, et al. Immunological identity of the small subunit of HLA antigens and β2 microglobulin and its turnover on the cell membrane. Proc Natl Acad Sci 1974; 71: 2123–2127
   PubMed Web of Science ®Google Scholar
• Grey H M, Kubo R T, Colon S M, et al. The small subunit of HLA antigens is β2 microglobulin. J Exp Med 1973; 138: 1608–1612
   PubMed Web of Science ®Google Scholar
• Cunningham B A, Berggard I. Structure, evolution and significance of β2 microglobulin. Transplant Rev 1974; 21: 3–14
   PubMedGoogle Scholar
• Bernier G M, Cohen R J, Conrad M E. Microglobulinemia in renal failure. Nature 1968; 218: 598–599
   PubMed Web of Science ®Google Scholar
• Wibell L, Evrin P E, Berggard I. Serum β2 microglobulin in renal disease. Nephron 1973; 10: 320–331
   PubMed Web of Science ®Google Scholar
• Karlsson F A, Wibell L, Evrin P E. β2 microglobulin in clinical medicine. Scand J Clin Lab Invest 1980; 40: 27–37
   PubMed Web of Science ®Google Scholar
• Michalski J P, Daniels R E, Talal M, et al. β2 microglobulin and lymphocytic infiltration in Sjogren's syndrome. N Engl J Med 1975; 293: 1228–1231
   PubMed Web of Science ®Google Scholar
• Mornex J F, Revillard J P, Vincent C, et al. Elevated serum β2 microglobulin levels and Ciq-binding immune complexes in sarcoidosis. Biomedicine 1979; 31: 210–213
   PubMedGoogle Scholar
• Descos L, Andre C, Beorchia S, et al. Serum levels of β2 microglobulin. A new marker of activity in Crohn's disease. N Engl J Med 1979; 301: 440–441
   PubMed Web of Science ®Google Scholar
• Teasdal C, Mander A M, Fifield R, et al. Serum β2 microglobulin in controls and cancer patients. Clin Chem 1973; 78: 135–143
   Google Scholar
• Hallgren R, Nou E, Lundquist G. Serum β2 microglobulin in patients with bronchial carcinoma and controls. Cancer 1980; 45: 780–785
   PubMed Web of Science ®Google Scholar
• Rashid S A, Cooper E H, Axon A TR, et al. Serum β2 microglobulin in malignant and benign diseases of the stomach and pancreas. Biomedicine 1980; 33: 112–116
   PubMedGoogle Scholar
• Amplot P L, Adinolfi M. Serum β2 microglobulin and its prognostic value in lymphomas. Eur J Cancer 1978; 15: 791–796
   Web of Science ®Google Scholar
• Cassuto J P, Krebs B P, Viot G, et al. β2 microglobulin, a tumour marker of lymphoproliferative disorders. Lancet 1978; 2: 108–109
   PubMed Web of Science ®Google Scholar
• Norfolk O, Child J A, Cooper E H, et al. Serum β2 microglobulin in myetomatosis: Potential value in stratification and monitoring. Br J Cancer 1979; 39: 510–515
   PubMedGoogle Scholar
• Child J A, Spati B, Illingworth S, et al. Serum β2 microglobulin and C-reactive protein in the monitoring of lymphomas. Cancer 1980; 45: 318–326
   PubMed Web of Science ®Google Scholar
• Simonsson B, Wibell L, Nilsson K. β2 microglobulin in chronic lymphocytic leukemia. Scand J Haematol 1980; 24: 174–180
   PubMedGoogle Scholar
• Bataille R, Magub M, Grenier J, et al. Serum beta-2-microglobulin in multiple myeloma: Relation to presenting features and clinical status. Eur J Cancer Clin Oncol 1982; 18: 59–66
   PubMedGoogle Scholar
• Anderson H, Scarffe J H, Swindell R, et al. Serum β2 microglobulin in patients with non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol 1983; 19: 327–331
   PubMedGoogle Scholar
• Bataille R, Durie B G, Grenier J. Serum β2 microglobulin and survival duration in multiple myeloma: A simple reliable marker for staging. Br J Haematol 1983; 55: 439–447
   PubMed Web of Science ®Google Scholar
• Hagberg J, Killander A, Simonsson B. Serum β2 microglobulin in malignant lymphoma. Cancer 1982; 51: 2220–2225
   Web of Science ®Google Scholar
• Norfolk D R, Child J A, Roberts B E, et al. Serum beta-2-microglobulin in disorders of myeloid proliferation. Acta Haemat 1983; 69: 361–368
   PubMed Web of Science ®Google Scholar
• Bataille R, Grenier J, Sany J. Beta-2-microglobulin in myeloma: Optimal use for staging, prognosis, and treatment. A prospective study of 160 patients. Blood 1984; 63: 468–476
   PubMed Web of Science ®Google Scholar
• Constantinides I P, Pathouli C, Karvountzis G, et al. Serum β2 microglobulin in malignant lymphoproliferative disorders. Cancer 1985; 55: 2384–2389
   PubMed Web of Science ®Google Scholar
• Swanson R A, Tracy R P, Katzmnan J A, et al. β2 microglobulin determined by radioimmunoassay with monoclonal antibody. Clin Chem 1982; 28: 2033–2039
   PubMed Web of Science ®Google Scholar
• Playford R J, Dawnay A, Cattell W R, et al. The development of a fluoroimunoassay for β2 microglobulin in serum. Ann Clin Biochem 1985; 22: 166–170
   PubMed Web of Science ®Google Scholar
• Hazkomori S-I. Glycolipids of tumor cell membrane. Adv Cancer Res 1974; 18: 265–315
   Google Scholar
• Nigam V N, Cantero A. Polysaccharides in cancer: Glycoproteins and glycolipids. Adv Cancer Res 1973; 17: 1–80
   Google Scholar
• Winzler R J. Determinations of serum glycoproteins. Methods of Biochemical Analysis, Vol. 2, W Click. Interscience Publishers, New York 1955; 279–311
   Google Scholar
• Silver H KB, Rangel D M, Morton D L. Serum sialic acid elevations in malignant melanoma patients. Cancer 1978; 4: 1497–1499
   Google Scholar
• Moss A J, Bissada N K, Boyd M C, et al. Significance of protein-bound neuraminic acid levels in patients with prostatic and bladder carcinoma. Urology 1979; 13: 182–184
   PubMed Web of Science ®Google Scholar
• Silver H K, Kanin K A, Archibald E L, et al. Serum sialic acid elevation in malignant melanoma patients. Cancer Res 1979; 39: 5036–5042
   PubMed Web of Science ®Google Scholar
• Hogan-Ryan A, Fennelly J J, Jones J, et al. Serum sialic acid and CEA concentrations in human breast cancer. Br J Cancer 1980; 41: 587–592
   PubMed Web of Science ®Google Scholar
• Dnistrian A M, Schwartz M K. Plasma lipid-bound sialic acid and carcinoembryonic antigen in cancer patients. Clin Chem 1981; 27: 1737–1739
   PubMed Web of Science ®Google Scholar
• Dnistrian A M, Schwartz M K, Katopodis N, et al. Serum lipid-bound sialic acid as a marker in breast cancer. Cancer 1982; 50: 1815–1819
   PubMed Web of Science ®Google Scholar
• Horgan E I. Total and lipid-bound sialic acid levels in sera from patients with cancer. Clin Chem Acta 1982; 118: 327–331
   PubMed Web of Science ®Google Scholar
• Katopodis N, Hirshaut Y, Geller N L. Lipid associated sialic acid test for the detection of human cancer. Cancer Res 1981; 42: 1737–1739
   Google Scholar
• Erbil K M, Jones J D, Klee G G. Use and limitation of serum total and lipid bound sialic acid concentration as markers for colorectal cancer. Cancer 1985; 55: 404–409
   PubMed Web of Science ®Google Scholar
• Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genetics 1979; 5: 957–972
   PubMedGoogle Scholar
• Koprowski H, Herlyn M, Steplewski Z, et al. Specific antigen in serum of patients with colon carcinoma. Science 1981; 212: 53–55
   PubMed Web of Science ®Google Scholar
• Herlyn M, Sears H F, Steplewski Z, et al. Monoclonal antibody detection of a circulating tumor associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric and pancreatic carcinoma. J Clin Immunol 1982; 2: 135–140
   PubMed Web of Science ®Google Scholar
• Silverman B A, Rubinstein A. Serum lactate dehydrogenase levels in adults and children with acquired immune deficiency syndrome (AIDS) and AIDS-related complex: Possible indicator of B-cell proliferation and disease activity. Am J Med 1985; 78: 728–736
   PubMed Web of Science ®Google Scholar
• Gutman A B, Gutman E B. An “acid” phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest 1938; 17: 473–478
   PubMedGoogle Scholar
• Shulman S, Mamrod L, Gonder M J, et al. The detection of prostatic acid phosphatase by antibody reactions in gel diffusion. J Immunol 1964; 93: 474–480
   PubMed Web of Science ®Google Scholar
• Choe B K, Lillehoj H S, Dong M K, et al. Characterization of anti-genie sites of human prostatic acid phosphatase. Ann NY Acad Sci 1982; 390: 16–26
   PubMed Web of Science ®Google Scholar
• Maatman T J, Gupta M K, Montie J E. The role of serum prostatic acid phosphatase as a tumor marker in men with advanced adenocarcinoma of the prostate. J Urol 1984; 132: 58–60
   PubMed Web of Science ®Google Scholar
• Pappad A A, Gadsden R H. Prostatic acid phosphatase: Clinical utility in detection, assessment and monitoring carcinoma of the prostate. Ann Clin Lab Sci 1984; 14: 285–291
   PubMed Web of Science ®Google Scholar
• Schadt M J, Garnett J E, Grayhack J T. Biochemical markers in prostatic cancer. Urol Clin North Am 1984; 11: 253–267
   PubMed Web of Science ®Google Scholar
• Cooper J F, Foti A G. A radioimmunoassay for prostatic acid phosphatase. I. Methodology and range of normal male serum values. Invest Urol 1974; 12: 98–102
   Google Scholar
• Foti A G, Cooper J F, Herschman H, et al. Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase. N Engl J Med 1977; 297: 1357–1361
   PubMed Web of Science ®Google Scholar
• Chu T M, Wang M C, Scott W W, et al. Immunochemical detection of serum prostatic acid phosphatase. Methodology and clinical evaluation. Invest Urol 1978; 15: 319–323
   PubMedGoogle Scholar
• Killian C S, Varga F P, Lee C L, et al. Quantitative counter-immunoelectrophoresis assay for prostatic acid phosphatase. Invest Urol 1980; 18: 219–224
   PubMedGoogle Scholar
• Lee C L, Wang M C, Murphy G P, et al. A solid-phase fluorescent immunoassay for human prostatic acid phosphatase. Cancer Res 1978; 38: 2871–2878
   PubMed Web of Science ®Google Scholar
• Lee C L, Killian C S, Murphy G P, et al. A solid-phase immuno-absorbent assay for serum prostatic acid phosphatase. Clin Chim Acta 1980; 101: 209–216
   PubMed Web of Science ®Google Scholar
• Kuriyama M, Wang M C, Lee C L, et al. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. J Natl Cancer Inst 1982; 68: 99–105
   PubMed Web of Science ®Google Scholar
• Lee C L, Li C Y, Jou Y H, et al. Immunochemical characterization of prostatic acid phosphatase with monoclonal antibodies. Ann NY Acad Sci 1982; 390: 52–61
   PubMed Web of Science ®Google Scholar
• Foti A G, Heschman H, Cooper J F. Comparison of human prostatic acid phosphatase by measurement of enzymatic activity and by radioimmunoassay. Clin Chem 1977; 23: 95–99
   PubMed Web of Science ®Google Scholar
• Wajsman Z, Chu T M, Saroff J, et al. Two new, direct and specific methods of acid phosphatase determination. National Field Trial. Urol 1979; 13: 8–11
   PubMed Web of Science ®Google Scholar
• Romas N A, Shaw L M, Hsu K C, et al. Clinical comparison of immunologic assays for determining prostatic acid phosphatase. Ann NY Acad Sci 1982; 390: 140–109
   Google Scholar
• Bruce A W, Mahan D E. The role of prostatic acid phosphatase in the investigation and treatment of adenocarcinoma of the prostate. Ann NY Acad Sci 1982; 390: 110–121
   PubMed Web of Science ®Google Scholar
• Vihko F, Kontturi M, Lukkarinen O, et al. Screening for carcinoma of the prostate. Rectal examination, and enzymatic and radioimmunologic measurements of serum acid phosphatase compared. Cancer 1985; 56: 173–177
   PubMed Web of Science ®Google Scholar
• Guinan P, Bush I, Ray V, et al. The accuracy of the rectal examination in the diagnosis of prostate carcinoma. N Engl J Med 1980; 303: 499–503
   PubMed Web of Science ®Google Scholar
• Lee C L, Chu T M, Wajsman L Z, et al. Value of new fluorescent immunoassay for human prostatic acid phosphatase in prostate cancer. Urology 1980; 15: 338–341
   PubMed Web of Science ®Google Scholar
• Griffiths J C. Prostate-specific acid phosphatase: Re-evaluation of radioimmunoassay in diagnosing prostate disease. Clin Chem 1980; 26: 433–436
   PubMed Web of Science ®Google Scholar
• Griffiths J. The appropriate uses of prostatic acid phosphatase determination in the diagnosis of adenocarcinoma of the prostate. Ann NY Acad Sci 1982; 390: 100–103
   PubMed Web of Science ®Google Scholar
• Whitesel J A, Donohue R E, Mani J H, et al. Acid phosphatase: Its influence on the management of carcinoma of the prostate. J Urol 1984; 131: 70–71
   PubMed Web of Science ®Google Scholar
• Vihko P, Kontturi M, Lukkarinen O, et al. Immunoreactive prostatic acid phosphatase in prostatic cancer: Diagnosis and followup of patients. J Urol 1985; 133: 979–982
   PubMed Web of Science ®Google Scholar
• Killian C S, Vargas F P, Slack N H, et al. Prostatic-specific acid phosphatase versus acid phosphatase in monitoring patients with prostate cancer. Ann NY Acad Sci 1982; 390: 122–132
   PubMed Web of Science ®Google Scholar
• Tsung S W. Creatine kinase isoenzyme patterns in human tissues obtained at surgery. Clin Chem 1976; 22: 173–175
   PubMed Web of Science ®Google Scholar
• Van Steirteghem A C, Robertson E A, Zweig M H. Distribution of serum concentrations of creatine kinase MM and BB isoenzymes measured by radioimmunoassay. Clin Chim Acta 1979; 93: 25–28
   PubMed Web of Science ®Google Scholar
• Zweig M H, Van Steirteghem A C, Schecter A. Radioimmunoassay of creatine kinase isoenzymes in human serum: Isoenzyme BB. Clin Chem 1978; 24: 422–428
   PubMed Web of Science ®Google Scholar
• Zweig M H, Van Steirteghem A C. Assessment by radioimmunoassay of serum creatine kinase BB (CK-BB) as a tumor marker: Studies in patients with various cancers and a comparison of CK-BB concentrations to prostate acid phosphatase concentrations. J Natl Cancer Inst 1981; 66: 859–862
   Web of Science ®Google Scholar
• Abbott L B, Lott J A. Reactivation of serum creatine kinase isoenzyme BB in patients with malignancies. Clin Chem 1984; 30: 1861–1863
   PubMed Web of Science ®Google Scholar
• Lederer W H, Gerstbrein H L. Creatine kinase isoenzyme BB activity in serum of a patient with gastric cancer. Clin Chem 1976; 22: 1748–1749
   PubMed Web of Science ®Google Scholar
• Hoag G, Franks C, De Coteau W. Creatine kinase isoenzymes in serum of patients with cancer of various organs. Clin Chem 1978; 24: 1654
   PubMed Web of Science ®Google Scholar
• Coolen R B, Propay D A, Nosanchuk J S, et al. Elevation of brain-type creatine kinase from patients with carcinoma. Cancer 1979; 44: 1414–1418
   PubMed Web of Science ®Google Scholar
• Forman D L. The significance of creatine kinase (CK-BB) in metastatic cancer of the prostate. Ann Clin Lab Sci 1979; 9: 333–338
   PubMed Web of Science ®Google Scholar
• Silverman L M, Dermer G B, Zweig M H, et al. Creatine kinase BB: A new tumor-associated marker. Clin Chem 1979; 25: 1432–1435
   PubMed Web of Science ®Google Scholar
• Aleyassine H, Maclsaac S G. The diagnostic significance of serum creatine kinase-BB isoenzyme in adenocarcinoma of the prostate. Clin Biochem 1980; 13: 109–112
   PubMed Web of Science ®Google Scholar
• Cornbleet P S, Evans M D. Creatine kinase BB isoenzyme activity in patients with hematologic disorders. Clin Chem 1980; 26: 1635–1636
   PubMed Web of Science ®Google Scholar
• Thompson R J, Rubery E D, Jones H M. Radioimmunoassay of serum creatine kinase-BB as a tumor marker in breast cancer. Lancet 1980; 2: 673–675
   PubMed Web of Science ®Google Scholar
• Magnani J L, Nilsson B, Brockhaus M, et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialyated lacto-N-fucopentaose II. J Biol Chem 1982; 257: 14365–14369
   PubMed Web of Science ®Google Scholar
• Magnani J L, Steplewski Z, Koprowski H, et al. Identification of the gastrointestinal and pancreatic cancer associated antigen detected by monoclonal antibody 19–9 in the sera of patients as a mucin. Cancer Res 1983; 43: 5489–5492
   PubMed Web of Science ®Google Scholar
• Atkinson B F, Ernst C S, Herlyn M, et al. Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res 1982; 42: 4820–4823
   PubMed Web of Science ®Google Scholar
• Sears H F, Herlyn M, Del Villano B C, et al. Monoclonal antibody detection of a circulating tumor associated antigen II. A longitudinal evaluation of patients with colorectal cancer. J. Clin Immunol 1982; 2: 141–149
   Web of Science ®Google Scholar
• Ritts R E, Del Villano B C, Go V LW, et al. Initial clinical evaluation of immunoradiometric assay for CA 19–9 using the NCI serum bank. Int J Cancer 1984; 33: 339–345
   PubMed Web of Science ®Google Scholar
• Satake K, Kanazawa G, Kho I, et al. A clinical evaluation of carbohydrate antigen 19–9 and carcinoembryonic antigen in patients with pancreatic carcinoma. J Surg Oncol 1985; 29: 15–21
   PubMed Web of Science ®Google Scholar
• Tatsuta M, Yamakura H, Iishi H, et al. Values of CA 19–9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor. Cancer 1985; 56: 2669–2673
   PubMed Web of Science ®Google Scholar
• Gupta M K, Arciapa R, Bocci L, et al. Measurement of a monoclonal-antibody-defined antigen (CA 19–9) in the sera of patients with malignant and nonmalignant diseases. Cancer 1985; 56: 277–283
   PubMed Web of Science ®Google Scholar
• Jalanko H, Kuusela P, Roberts P, et al. Comparison of a new tumour marker, CA 19–9 (TM), with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal disease. J Clin Pathol 1984; 37: 218–222
   PubMed Web of Science ®Google Scholar
• Kuusela P, Jalanko H, Roberts P, et al. Comparison of CA 19–9 and carcinoembryonic antigen (CEA) levels in serum of patients with colorectal diseases. Br J Cancer 1984; 49: 135–138
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Tishida K, Tanigawa M, et al. Carbohydrate anti-genie determinant (CA 19–9) and other tumor markers in gastrointestinal malignancies. Digest 1985; 31: 67–76
   PubMed Web of Science ®Google Scholar
• Bast R C, Jr, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331–1337
   PubMed Web of Science ®Google Scholar
• Kabawat S E, Bast R C, Jr, Welch W R, et al. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometroid, and clear cell type. Am J Clin Pathol 1983; 79: 98–104
   PubMed Web of Science ®Google Scholar
• Masuho Y, Zalutsky M, Knapp R C, et al. Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. Cancer Res 1984; 44: 2813–2819
   PubMed Web of Science ®Google Scholar
• Klug T L, Bast R C, Jr, Niloff J M, et al. A monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res 1984; 44: 1048–1053
   PubMed Web of Science ®Google Scholar
• Bast R C, Jr, Klug T L, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883–887
   PubMed Web of Science ®Google Scholar
• Bast R C, Jr, Klug T L, Schaetzl E, et al. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19–9, and carcinoembryonic antigen. Am J Obstet Gynecol 1984; 149: 553–559
   PubMed Web of Science ®Google Scholar
• Canney P A, Moore M, Wilkinson P M, et al. Ovarian cancer antigen CA 125: A prospective clinical assessment of its role as a tumor marker. Br J Cancer 1984; 50: 765–769
   PubMed Web of Science ®Google Scholar
• Heinonen P K, Tontti K, Koivula T, et al. Tumor-associated antigen CA 125 in patients with ovarian cancer. Br J Obstet Gynecol 1985; 92: 528–531
   PubMedGoogle Scholar
• Ricolleau G, Chatal J, Fumoleau P, et al. Radioimmunoassay of the CA 125 antigen in ovarian carcinomas: Advantages compared to CA 19–9 and CEA. Tumour Biol 1984; 5: 151–159
   PubMedGoogle Scholar
• Niloff J M, Klug T L, Schaetzl E, et al. Elevation of serum CA 125 in carcinomas of the fallopian tube, endometrium and endo-cervix. Am J Obstet Gynecol 1984; 148: 1057–1058
   PubMed Web of Science ®Google Scholar
• Niloff J M, Bast R C, Jr, Schaetzl E, et al. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol 1985; 151: 981–986
   PubMed Web of Science ®Google Scholar